Monitoring patients with severe tricuspid regurgitation in Hamburg
Tricuspid Regurgitation Hamburg Cohort
This study is looking at patients with serious tricuspid regurgitation to see what factors can help predict their health outcomes and improve treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Universitätsklinikum Hamburg-Eppendorf Academic / other |
| Locations | 1 site (Hamburg) |
| Trial ID | NCT04755842 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients with clinically relevant tricuspid regurgitation (TR), a condition linked to high mortality rates. It aims to identify predictors of outcomes in patients suffering from TR, particularly in the context of left-sided heart disease, pulmonary hypertension, or atrial fibrillation. The study will monitor these patients to improve risk prediction for various treatment options, including medical, surgical, and interventional approaches. The research is conducted at the University Heart and Vascular Center Hamburg.
Who should consider this trial
Good fit: Ideal candidates are individuals over 18 years old with clinically relevant tricuspid regurgitation of at least Grade III.
Not a fit: Patients who are unable to understand the study documents due to language barriers or those who cannot cooperate due to physical or psychological issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance treatment strategies and outcomes for patients with severe tricuspid regurgitation.
How similar studies have performed: While the study addresses a significant clinical issue, the approach of monitoring and defining predictors in this specific cohort is relatively novel and has not been extensively tested in similar studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Ability to provide written informed consent in accordance with Good Epidemiological Practice and local legislation. * Individuals over the age of 18 years. * Patients with clinically relevant tricuspid regurgitation (≥ severe TR, at least Grade III of V) Exclusion Criteria: * Insufficient knowledge of the German language, to understand study documents and interview without translation * Physical or psychological incapability to cooperate in the investigation
Where this trial is running
Hamburg
- University Heart and Vascular Center Hamburg — Hamburg, Germany (Recruiting)
Study contacts
- Principal investigator: Daniel Kalbacher, MD — University Heart and Vascular Center Hamburg
- Study coordinator: Benedikt Koell, MD
- Email: b.koell@uke.de
- Phone: +494074100
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.